FLUORESCITE- fluorescein sodium injection, solution Alcon, Inc.

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FLUORESCITE[®] safely and effectively. See full prescribing information for FLUORESCITE[®] (fluorescein injection, USP) 10%.

FLUORESCITE[®] (fluorescein injection, USP) 10% Intravenous injection

Initial U.S. Approval: 1976

INDICATIONS AND USAGE
FLUORESCITE [®] Injection 10% is indicated in diagnostic fluorescein angiography or angioscopy of the retina
and iris vasculature. (1)

The normal adult dose of FLUORESCITE[®] Injection 10% (100 mg/mL) is 500 mg via intravenous administration. (2.1)

For children, the dose should be calculated on the basis of 7.7 mg for each kg of actual body weight (or 35 mg for each 10 pounds of body weight) up to a maximum of 500 mg via intravenous administration. (2.1)

DOSAGE FORMS AND STRENGTHS					
Single use 5 mL vial containing 100 mg/mL fluorescein. (3)					
CONTRAINDICATIONS					
FLUORESCITE [®] Injection 10% is contraindicated in patients with known hypersensitivity to fluorescein sodium or any other ingredients in this product (4.1)					

The most common adverse reactions include skin discoloration, urine discoloration, nausea, vomiting, and gastrointestinal distress. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Alcon Laboratories, Inc. at 1-800-757-9195 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 5/2021

FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE

T INDICATIONS AND USAGE

- 2 DOSAGE AND ADMINISTRATION
 - 2.1 Dosing
 - 2.2 Preparation for Administration
 - 2.3 Administration

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Respiratory Reactions
- 5.2 Severe Local Tissue Damage
- 5.3 Nausea and/or Vomiting

6 ADVERSE REACTIONS

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.3 Nursing Mothers
- 8.4 Pediatric Use
- 8.5 Geriatric Use

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

16 HOW SUPPLIED/STORAGE AND HANDLING

- 16.1 How Supplied
- 16.2 Storage

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

FLUORESCITE[®] Injection 10% is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature.

2 DOSAGE AND ADMINISTRATION

2.1 Dosing

Adult Dose- The normal adult dose of FLUORESCITE $^{\mbox{\scriptsize B}}$ Injection 10% (100 mg/mL) is 500 mg via intravenous administration.

For children, the dose should be calculated on the basis of 7.7 mg for each kg of actual body weight (or 35 mg for each 10 pounds of body weight) up to a maximum of 500 mg via intravenous administration.

2.2 Preparation for Administration

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not mix or dilute with other solutions or drugs. Flush intravenous cannulas before and after drugs are injected to avoid physical incompatibility reactions.

2.3 Administration

Inject the dose rapidly (1 mL per second is normally recommended) intravenously into the antecubital vein, after taking precautions to avoid extravasation. A syringe, filled with FLUORESCITE[®], may be attached to transparent tubing and a 23 gauge butterfly needle for injection. Insert the needle and draw the patient's blood to the hub of the syringe so that a small air bubble separates the patient's blood in the tubing from the fluorescein. With the room lights on, slowly inject the blood back into the vein while watching the skin over the needle tip. If the needle has extravasated, the patient's blood will be seen to bulge the skin and the injection should be stopped before any fluorescein is injected. When assured that extravasation has not occurred, the room light may be turned off and the fluorescein injection completed. Luminescence usually appears in the retina and choroidal vessels in 7 to 14 seconds and can be observed by standard viewing equipment.

Reduction in dose from 5 mL to 2 mL of FLUORESCITE[®] Injection 10% may be appropriate in cases when a highly sensitive imaging system e.g., scanning laser ophthalmoscope is used.

3 DOSAGE FORMS AND STRENGTHS

Single use 5 mL vial containing 100 mg/mL fluorescein.

4 CONTRAINDICATIONS

FLUORESCITE[®] Injection 10% is contraindicated in patients with known hypersensitivity to fluorescein sodium or any other ingredients in this product. Rare cases of death due to anaphylaxis have been reported. [see Warnings and Precautions (5.1) and Adverse Reactions (6)].

Fluorescein sodium can induce serious intolerance reactions. These reactions of intolerance are always unpredictable but they are more frequent in patients who have previously experienced an adverse reaction after fluorescein injection (symptoms other than nausea and vomiting) or in patients with history of allergy such as food or drug induced urticaria, asthma, eczema, allergic rhinitis.

Detailed questioning of each patient is recommended before the angiography to evaluate any prior history of allergy.

5 WARNINGS AND PRECAUTIONS

5.1 Respiratory Reactions

Caution is to be exercised in patients with a history of allergy or bronchial asthma. An emergency tray should be available in the event of possible reaction to FLUORESCITE[®] Injection 10%.

If a potential allergy is suspected, an intradermal skin test may be performed prior to intravenous administration, i.e., 0.05 mL injected intradermally to be evaluated 30 to 60 minutes following injection. Given the sensitivity and specificity of skin testing, a negative

skin test is not proof that a patient is not allergic to fluorescein.

5.2 Severe Local Tissue Damage

Care must be taken to avoid extravasation during injection as the high pH of fluorescein solution can result in severe local tissue damage. The following complications resulting from extravasation of fluorescein have been noted to occur: severe pain in the arm for several hours, sloughing of the skin, superficial phlebitis, subcutaneous granuloma, and toxic neuritis along the median curve in the antecubital area. When significant extravasation occurs, the injection should be discontinued and conservative measures to treat damaged tissue and to relieve pain should be implemented. [see Administration (2.3) and Adverse Reactions(6)].

5.3 Nausea and/or Vomiting

Nausea and/or vomiting and gastrointestinal distress occur commonly within the first few minutes following injection. These reactions usually subside within 10 minutes.

6 ADVERSE REACTIONS

Skin and Urine Discoloration

The most common reaction is temporary yellowish discoloration of the skin and urine. Urine may attain a bright yellow color. Discoloration of the skin usually fades in 6 to 12 hours and usually fades in urine in 24 to 36 hours.

Gastrointestinal Reactions

Nausea, vomiting, and gastrointestinal distress are common adverse events. A strong taste may develop after injection.

Hypersensitivity Reactions

Symptoms and signs of hypersensitivity have occurred. Generalized hives and itching, bronchospasm and anaphylaxis have been reported. Rare cases of death have been reported. [see Contraindications (4.1) and Warnings and Precautions (5.1)].

Cardiopulmonary Reactions

Cardiac arrest, basilar artery ischemia, severe shock and death may occur rarely.

Neurologic Reactions

Headache may occur. Convulsions and syncope may rarely occur following injection.

Thrombophlebitis

Thrombophlebitis at the injection site has been reported. Extravasation of the solution at the injection site causes intense pain at the site and a dull aching pain in the injected arm. [see Administration (2.3) and Warnings and Precautions (5.2)].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Adequate animal reproduction studies have not been conducted with fluorescein sodium. It is also not known whether fluorescein sodium can cause fetal harm when administered to a pregnant woman. Fluorescein sodium should be given to a pregnant woman only if clearly needed.

8.3 Nursing Mothers

Fluorescein sodium injection has been demonstrated to be excreted in human milk for up to 4 days. Following fluorescein angiography, breast-feeding should therefore be discontinued for at least 4 days and the milk should be pumped off and discarded during this period.

8.4 Pediatric Use


Pediatric patients have been included in clinical studies. No overall differences in safety or effectiveness have been observed between pediatric and adult patients.

8.5 Geriatric Use

No overall differences in safety or effectiveness have been observed between elderly and other adult patients.

11 DESCRIPTION

FLUORESCITE[®] (fluorescein injection, USP) 10% contains fluorescein sodium (equivalent to fluorescein 10% w/v). It is a sterile solution for use intravenously as a diagnostic aid. Its chemical name is spiro[isobenzofuran-1(3H),9'-[9H]xanthene]-3-one, 3'6'-dihydroxy, disodium salt. The active ingredient is represented by the chemical structure:



376.27 MW

FLUORESCITE[®] (fluorescein injection, USP) 10% is supplied as a sterile, unpreserved, unit dose aqueous solution, that has a pH of 8.0 - 9.8 and an osmolality of 572-858 mOsm/kg.

Active ingredient: fluorescein sodium

Inactive Ingredients: Sodium hydroxide and/or hydrochloric acid (to adjust pH), and water for injection.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Fluorescein sodium responds to electromagnetic radiation and light between the wavelengths of 465-490 nm and fluoresces, i.e., emits light at wavelengths of 520-530 nm. Thus, the hydrocarbon is excited by blue light and emits light that appears yellowish-green. Following intravenous injection of fluorescein sodium in an aqueous solution, the unbound fraction of the fluorescein can be excited with a blue light flash from a fundus camera as it circulates through the ocular vasculature, and the yellowish green fluorescence of the dye is captured by the camera. In the fundus, the fluorescence of the dye demarcates the retinal and/or choroidal vasculature under observation, distinguishing it from adjacent areas/structures.

12.3 Pharmacokinetics

Distribution:

Within 7 to 14 seconds after intravenous (IV) administration into antecubital vein, fluorescein usually appears in the central artery of the eye. Within a few minutes of IV administration of fluorescein sodium, a yellowish discoloration of the skin occurs, which begins to fade after 6 to 12 hours of dosing. Various estimates of volume of distribution indicate that fluorescein distributes well into interstitial space (0.5 L/kg).

Metabolism:

Fluorescein undergoes rapid metabolism to fluorescein monoglucuronide. After IV administration of fluorescein sodium (14 mg/kg) to 7 healthy subjects, approximately 80% of fluorescein in plasma was converted to glucuronide conjugate after a period of 1 hour post dose, indicating relatively rapid conjugation.

Excretion:

Fluorescein and its metabolites are mainly eliminated via renal excretion. After IV administration, the urine remains slightly fluorescent for 24 to 36 hours. A renal clearance of 1.75 mL/min/kg and a hepatic clearance (due to conjugation) of 1.50 mL/min/kg have been estimated. The systemic clearance of fluorescein was essentially complete by 48 to 72 hours after administration of 500 mg fluorescein.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

There have been no long-term studies done using fluorescein in animals to evaluate carcinogenic potential.

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

FLUORESCITE[®] (fluorescein injection, USP) 10% is supplied in a single use 5 mL glass vial with a gray FluroTec coated chlorobutyl stopper and purple flip-off aluminum seal. The vial stopper is not made with natural rubber latex. The vial contains a sterile, red-orange solution of fluorescein sodium.

NDC 0065-0092-65

16.2 Storage

Store at 2°- 25°C (36°- 77°F). Do Not Freeze

17 PATIENT COUNSELING INFORMATION

After administration of fluorescein sodium, skin will attain a temporary yellowish discoloration. Urine attains a bright yellow color. Discoloration of the skin usually fades in 6 to 12 hours and usually fades in urine in 24 to 36 hours. [*see Adverse Reactions (6)*]

Distributed By: ALCON LABORATORIES, INC.

Fort Worth, Texas 76134 USA

© 2006, 2016 Novartis

Revised: 2/2016

9014068-0117

PRINCIPAL DISPLAY PANEL

NDC 0065-0092-65

1 Dozen 5 mL Vials

Florescite[®] 10%

(fluorescein injection, USP) 10% STERILE 100 mg/mL Fluorescein

Rx Only

FOR INTRAVENOUS USE

Store at 2° - 25° C (36° - 77° F)

Do Not Freeze

Alcon®


ALCON LABORATORIES, INC. Fort Worth, Texas 76134 USA

©2000-2009 Alcon, Inc.

H11427-1009

LOT:

EXP.:



NDC 0065-0092-65

1 Dozen 5 mL Vials

Florescite^{*} 10%

(fluorescein injection, USP) 10% STERILE 100 mg/mL Fluorescein

Rx Only

FOR INTRAVENOUS USE

Store at 2° - 25° C (36° - 77° F)

Do Not Freeze

Alcon[®] a Novartis company

Alcon Laboratories, Inc.

Fort Worth, Texas 76134 USA * a trademark of Norvatis © 2000, 2009, 2015 Novartis


GTIN: 10300650092651

S/N:

LOT:

EXP.:

9010833-0615



NDC 0065-0092-65

Fluorescite[®] 10%

(fluorescein injection, USP) 10% 100 mg/mL FLUORESCEIN

5 mL STERILE

ALCON LABORATORIES, INC. Fort Worth, Texas 76134 USA


©2000-2009 Alcon, Inc.

Rx Only

H11426-0209

LOT:

EXP.:



FLUORESCITE						
fluorescein sodium injection,	solution					
Product Information						
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)		NDC:0065-0092		
Route of Administration	OPHTHALMIC					
Active Ingredient/Active Moiety						
Ingre	dient Name		Basis of Strength	Strength		
FLUORESCEIN SODIUM (UNII: 93) UNII:TPY09G7XIR)	(55PE38X) (FLUORESCEIN -		FLUORESCEIN	100 mg in 1 mL		
Inactive Ingredients						
	Ingredient Name			Strength		
SODIUM HYDROXIDE (UNII: 55X04	QC32I)					
HYDROCHLORIC ACID (UNII: QTT)	L7582CB)					
WATER (UNII: 059QF0KO0R)						

Packaging							
#	ltem Code	Package Description	Mark	ceting Start Date	Marketing End Date		
1	NDC:0065-0092- 05	12 in 1 CARTON	09/15/19	972	10/31/2013		
1		5 mL in 1 VIAL; Type 0: Not a Combination Product					
2	NDC:0065-0092- 65	12 in 1 CARTON	09/15/1972				
2		5 mL in 1 VIAL; Type 0: Not a Combination Product					
Marketing Information							
					Mayleating End		
Marketing Category		Application Number or Monograph Citation	oh Marketing Start Date		Marketing End Date		
	DA	NDA021980	00/1	5/1972			

Labeler - Alcon, Inc. (008018525)

Registrant - Alcon Research LLC (007672236)

Establishment

Name	Address	ID/FEI	Business Operations
Alcon Research LLC		007672236	manufacture(0065-0092)

Establishment

Name	Address	ID/FEI	Business Operations
INTERNATIONAL MEDICATION SYSTEMS, LIMITED		055750020	MANUFACTURE(0065-0092)

Revised: 12/2023

Alcon, Inc.